Zydus Lifesciences Limited – 9/5/2025

Representatives of the FDA were fortunate to attend a community discussion on advancing clinical trial diversity for sexual and gender minority communities to help improve the generalizability of trial results across the entire population of patients who may use medical products.

This communication is part of the Communications Pilot to Enhance the Medical Device Recall Program

Compounding Pharmacy/Misbranded

Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet

Unapproved New Drugs/Misbranded

FDA strongly encourages companies to continue to develop new, reliable ways to minimize animal testing and to provide the data necessary for the FDA to make a GRASE determination for sunscreen active ingredients.